HR 5811
115th Congress
House
Health
Drug safety, medical device, and laboratory regulation
Drug trafficking and controlled substances
Licensing and registrations
Prescription drugs
Long-Term Opioid Efficacy Act of 2018
Introduced: May 15, 2018
See on congress.gov
Everywhere this bill has been
11 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 20, 2018
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Jun 19, 2018
Motion to reconsider laid on the table Agreed to without objection.
Jun 19, 2018
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5243)
Jun 19, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5811.
Jun 19, 2018
Considered under suspension of the rules. (consideration: CR H5243-5244)
Jun 19, 2018
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Jun 19, 2018
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5243)
May 17, 2018
Ordered to be Reported (Amended) by Voice Vote.
May 17, 2018
Committee Consideration and Mark-up Session Held.
May 15, 2018
Referred to the House Committee on Energy and Commerce.
May 15, 2018
Introduced in House
Plain-English summary
Long-Term Opioid Efficacy Act of 2018
This bill expands the authority of the Food and Drug Administration (FDA) to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).
What's happening now
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committees of jurisdiction
2